Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int Wound J ; 21 Suppl 1: 9-24, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38393140

RESUMO

The availability of new products and strategies to manage wounds has taken a quantum leap in recent years. Healthcare professionals now have an extensive range of products to choose from, but while positive this also raises dilemmas in real-world clinical practice to decide on the most appropriate treatment for a given patient. Clinical trials confirm the effectiveness of the unique combination of hyaluronic acid and amino acids (Vulnamin®) in a range of wounds, but are these results replicated in real-world clinical practice? International experts presented their clinical experience with the use of the combination in difficult-to-treat wounds. The objective was to reach a consensus on how and when to use the unique combination products to provide a cost-effective, convenient option, in all healthcare settings that improves QoL for patients and their carers.


Assuntos
Aminoácidos , Ácido Hialurônico , Humanos , Ácido Hialurônico/uso terapêutico , Aminoácidos/uso terapêutico , Qualidade de Vida
2.
Int Wound J ; 7(6): 438-47, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20659185

RESUMO

Treatment of chronic leg ulcers remains a major health care issue. Although many reports have examined different topical dressings, none have specifically looked at microcrystalline cellulose (MCC). We aimed to evaluate in a prospective, open study the safety and performance of a MCC membrane (Veloderm) in a series of chronic leg wounds of different aetiology. Fifty-five patients participated in this study. The membrane was applied every 5-10 days for 1 month, immediately after surgical debridement. The wound bed was assessed on days 7, 15 and 30 for erythema, pain, exudate level and infection. The wound size change at 30 days was the primary efficacy parameter and any adverse events were collected and analysed. A wound size change of 55% was achieved at the end of follow-up, with an improvement in all the collected parameters, but the erythema, which showed a mild increase. To date, this is the largest experience with a MCC product in chronic wounds. Our study suggests that this treatment may be safe and useful and deserves further investigation.


Assuntos
Úlcera da Perna/terapia , Polissacarídeos/uso terapêutico , Higiene da Pele/métodos , Cicatrização , Administração Tópica , Adulto , Idoso , Idoso de 80 Anos ou mais , Desbridamento , Eritema/etiologia , Exsudatos e Transudatos , Feminino , Humanos , Úlcera da Perna/etiologia , Úlcera da Perna/patologia , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Dor/etiologia , Estudos Prospectivos , Índice de Gravidade de Doença , Resultado do Tratamento , Infecção dos Ferimentos/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA